Immunoglobulin Market Overview:
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
5% Concentration
10% Concentration
Others
Sucutaneous
16.5% Concentration
20% Concentration
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
Brazil
Turkey
Argentina
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
CSL Ltd.
Grifols S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB group
Biotest AG
China Biologics Products, Inc.
Shire Plc.(Baxalta)
Bayer AG
The other players of the immunoglobulin market include (companies not profiled in the report):
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
5% Concentration
10% Concentration
Others
Sucutaneous
16.5% Concentration
20% Concentration
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
Brazil
Turkey
Argentina
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
CSL Ltd.
Grifols S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB group
Biotest AG
China Biologics Products, Inc.
Shire Plc.(Baxalta)
Bayer AG
The other players of the immunoglobulin market include (companies not profiled in the report):
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc
Note: Product cover images may vary from those shown
CHAPTER 1: INTRODUCTION
Chapter 2: EXECUTIVE SUMMARY
Chapter 3: MARKET OVERVIEW
Chapter 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
Chapter 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
Chapter 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
Chapter 7: IMMUNOGLOBULIN MARKET, BY REGION
Chapter 8: COMPANY PROFILES
List Of Tables
List of Figures
Note: Product cover images may vary from those shown
According to this report titled, 'Immunoglobulin Market by Application, Product Type, and Mode of Delivery: Global Opportunity Analysis and Industry Forecast, 2018-2025', the immunoglobulin market accounted for $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, and is used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the immunoglobulin market.
Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 toward market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Immunoglobulin Market:
Myasthenia Gravis segment is projected to grow at the fastest rate during the analysis period.
Hypogammaglobulinemia was the highest revenue contributor in 2017 and is expected to continue its dominance during the forecast period.
North America dominated global immunoglobulins market and is projected to grow at a CAGR of 7.3%.
Saudi Arabia is expected to grow at the fastest rate in the LAMEA region, registering a CAGR of 9.1%.
LAMEA was the fastest growing segment growing at a CAGR of 10.2%.
In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of the immunoglobulin market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and the presence of large plasma production facilities.
The key companies profiled in the report include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare.
Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, and is used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the immunoglobulin market.
Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 toward market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Immunoglobulin Market:
Myasthenia Gravis segment is projected to grow at the fastest rate during the analysis period.
Hypogammaglobulinemia was the highest revenue contributor in 2017 and is expected to continue its dominance during the forecast period.
North America dominated global immunoglobulins market and is projected to grow at a CAGR of 7.3%.
Saudi Arabia is expected to grow at the fastest rate in the LAMEA region, registering a CAGR of 9.1%.
LAMEA was the fastest growing segment growing at a CAGR of 10.2%.
In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of the immunoglobulin market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and the presence of large plasma production facilities.
The key companies profiled in the report include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare.
Note: Product cover images may vary from those shown
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
